A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
Clinical trial NCT03767829 · TERMINATED
Trial details
- NCT number
- NCT03767829
- Sponsor
- Alnylam Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-05
- Primary completion
- 2020-06-25
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.